Navigation Links
ImaRx to Report Corporate Updates and 4Q07 Financial Results
Date:3/20/2008

Live Webcast and Conference Call Scheduled for Thursday, March 27TH AT 5 PM

ET

TUCSON, Ariz., March 20 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company will host a live webcast and conference call on Thursday, March 27, 2008, at 5:00 p.m. ET to discuss corporate updates and fourth quarter 2007 financial results.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407- 4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through April 3, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 279436).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its FDA approved product, urokinase, for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

Cautionary Statement For The Purpose Of The "Safe Harbor" Provisions Of The Private Securities Litigation Reform Act of 1995

Note: Statements made in this press release which are not historical in nature constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements include but are not limited those related to our efforts to grow the marketplace for urokinase, our intent to reduce our operating expenses associated with our SonoLysis development and our belief that we will allow the Company to explore additional therapeutic applications for the product. These statements are based on management's current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. Such risks and uncertainties include but are not limited to: sales of and demand for urokinase may decline, the FDA may not approve our future requests for urokinase lot releases or approval of expanded uses of urokinase beyond treatment of acute massive pulmonary emboli, we may not be able to complete definitive documentation with Microbix on the terms of our letter of intent, Microbix may not be able to perfect the manufacturing process or to secure approval from the FDA to manufacture urokinase, we may not be effective in our marketing efforts for urokinase, and we may not have or be able to secure sufficient capital to fund our operations and the development and commercialization of our product candidates. All information in this press release is as of January 30, 2008, and the Company undertakes no duty to update this information. A more complete description of these risks can be found in the Company's filings with the Securities and Exchange Commission.

Contacts:

The Ruth Group

Sara Ephraim (investors)

646-536-7002

sephraim@theruthgroup.com

Jason Rando (media)

646-536-7025

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. Bioheart, Inc. to Report Full Year 2007 Financial Results on Thursday, March 27, 2008
3. Genetic Engineering & Biotechnology News reports on clinical trials in developing countries
4. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
5. Vion Reports 2007 Fourth Quarter and Year-End Results
6. AutoImmune Inc. Reports 2007 Fourth Quarter and Year End Financial Results
7. Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
8. Warner Chilcott Reports the Death of Its Director James Andress
9. Nile Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
10. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
11. Unigene Restates Policy on Analyst Reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... The Board of ... appointment of John Tilton as Chief Commercial Officer.  Mr. Tilton joined Biohaven from ... founding commercial leaders responsible for the commercialization of multiple orphan drug indications. ...
(Date:4/27/2016)... ... 27, 2016 , ... A compact PET scanner called NuPETâ„¢ ... (Magnetic Resonance Imaging) in existing third-party MRI systems. PET and MRI are complementary ... subjects. Simultaneous PET/MRI imaging offers a solution to many challenges that face researchers ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth , ... joined the company as Chief Business Officer. Arianpour, a genomics pioneer and visionary ... market, was most recently Chief Commercial Officer of Pathway Genomics. He has held ...
Breaking Biology Technology:
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/10/2016)... PUNE, India , March 10, 2016 ... to a new market research report "Identity and Access ... SSO, & Audit, Compliance, and Governance), by Organization Size, ... Forecast to 2020", published by MarketsandMarkets, The market is ... to USD 12.78 Billion by 2020, at a Compound ...
Breaking Biology News(10 mins):